RBC Capital analyst Gregory Renza maintained a Buy rating on ACADIA Pharmaceuticals (NASDAQ:ACAD) Inc on Monday, setting a price target of $32, which is approximately 51.09% above the present share price of $21.18.
Renza expects ACADIA Pharmaceuticals Inc to post earnings per share (EPS) of -$0.42 for the second quarter of 2021.
The current consensus among 20 TipRanks analysts is for a Moderate Buy rating of shares in ACADIA Pharmaceuticals, with an average price target of $32.18.
The analysts price targets range from a high of $63 to a low of $20.
In its latest earnings report, released on 12/31/2020, the company reported a quarterly revenue of $121.01 million and a net profit of -$67.16 million. The company's market cap is $3.39 billion.
According to TipRanks.com, RBC Capital analyst Gregory Renza is currently ranked with 3 stars on a 0-5 stars ranking scale, with an average return of 10.0% and a 39.51% success rate.
ACADIA Pharmaceuticals, Inc. operates as a biopharmaceutical company focused on the development and commercialization of medicines to address unmet medical needs in central nervous system, or CNS, disorders. The firms product include Nuplazid, which is used for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. The company was founded by Mark R. Brann on July 16, 1993 and is headquartered in San Diego, CA.